Metachromatic Leukodystrophy Market
Expected launch of potential therapies may increase Metachromatic Leukodystrophy Market Size in the coming years, assisted by an increase in prevalent population of MLD. Owing to the positive outcomes of the several drug candidates during the developmental stage by key players such as Orchard Therapeutics (OTL-200), Takeda (TAK-611), Magenta Therapeutics (MGTA-456) and others have the potential to create a significant positive shift in the MLD Market Size.
However, the current treatment paradigm of MLD includes use of medications, physical therapy, occupational and speech therapy, nutritional assistance and bone marrow transplantation.
Currently the market holds no effective treatment to reverse the deterioration and loss of function that MLD causes. Treatment for the condition focuses on managing symptoms and improving your quality of life i.e. it’s generally supportive in nature.
The management of MLD can be done by using medications, physical, occupational and speech therapy and nutritional assistance can help the patients suffering from MLD. Bone marrow transplantation may delay progression of the disease in some infantile-onset cases.
Medications, mainly pain killers can be used which may reduce the signs and symptoms and thereby relieving muscle pain.
The signs and symptoms of MLD that can be resolved using medicines include such as behavioural problems, seizures, difficulty with sleeping, gastrointestinal issues, infection and pain. Physical therapy can help by curing stiffness in the joints to get short-term relief.
One can rely on a wheelchair, walker or other assistive devices as the condition progresses.
Comments
Post a Comment